Pharmacy

Your Article Summary

See Latest Articles

Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study
Active Biotech, 06/09/09

Active Biotech announced that patient enrollment to the Phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed after enrollment of 200 patients into the study, according to the clinical protocol. The study is a 2:1 randomized, placebo-controlled, double-blind Phase II study of 1 mg/day TASQ versus placebo. The study encompasses symptom-free patients with metastatic, hormone-resistant, prostate cancer.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Lundbeck, 11/30/09

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

 See all of Drug Trials

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

A Multicenter, Double-Blind, Randomized, Parallel Group Study Comparing Polyvinyl Chloride and Polyvinyl Chloride-Free Catheter Materials
The Journal of Urology, 11/24/09

Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09

Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkins Lymphoma
Cephalon, 11/06/09

 See all of Major Studies